Wegovy recommended for approval for the treatment of obesity by the CHMP.
Wegovy is a once-weekly semaglutide 2.4 mg injection for chronic weight management in adults living with obesity (initial BMI greater than 30 kg/m2) or overweight (initial BMI greater than 27 kg/m2) with at least one weight-related comorbidity such as high blood pressure, heart disease or type 2 diabetes.
The positive CHMP opinion is based on results from the STEP phase IIIa clinical trial programme. Across the trials in people with obesity or overweight without type 2 diabetes, an average weight loss of 17-18% sustained over 68 weeks was reported for those treated with Wegovy. Wegovy demonstrated a safe and well-tolerated profile across the programme, with the most common adverse events being gastrointestinal.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins